Faculty Profiles - KANDA Mitsuro

Papers - KANDA Mitsuro

Division display 441 - 460 of about 573 ／ All the affair displays >>

Conversion surgery for unresectable gastric cancer following complete response of distant metastasis by systemic chemotherapy.

Kobayashi Daisuke, Kanda Mitsuro, Tanaka Chie, Iwata Naoki, Hayashi Masamichi, Yamada Suguru, Nakayama Goro, Sugimoto Hiroyuki, Koike Masahiko, Fujii Tsutomu, Fujiwara Michitaka, Kodera Yasuhiro

JOURNAL OF CLINICAL ONCOLOGY Vol. 35 ( 4 ) page： . 2017.2

The COMET Open-label Phase II Study of Neoadjuvant FOLFOX or XELOX Treatment Combined with Molecular Targeting Monoclonal Antibodies in Patients with Resectable Liver Metastasis of Colorectal Cancer. Reviewed International journal

Masato Kataoka, Mitsuro Kanda, Kiyoshi Ishigure, Hiroshi Matsuoka, Yusuke Sato, Takao Takahashi, Chihiro Tanaka, Tomohiro Deguchi, Yoshihisa Shibata, Mikinori Sato, Hitoshi Inagaki, Takanori Matsui, Akinobu Kondo, Nao Takano, Haruyoshi Tanaka, Junichi Sakamoto, Koji Oba, Ken Kondo

Annals of surgical oncology Vol. 24 ( 2 ) page： 546 - 553 2017.2

Language：Japanese Publishing type：Research paper (scientific journal)

BACKGROUND: Advantages of neoadjuvant chemotherapy combined with monoclonal antibodies for treating patients with resectable colorectal cancer liver metastasis (CLM) have not been established. The purpose of this study was to evaluate the efficacy and safety of oxaliplatin-based regimen (FOLFOX or XELOX) plus monoclonal antibodies (cetuximab or bevacizumab) treatment in patients with resectable CLM. METHODS: A single-arm, open-label, multicenter, phase II trial was conducted for patients aged ≥ 20 years with resectable and untreated CLM. Patients received preoperative FOLFOX (6 cycles) or XELOX (4 cycles). Cetuximab or bevacizumab was administered to patients with wild-type or mutated KRAS codons 12 and 13, respectively. The primary endpoint was progression-free survival (PFS). RESULTS: Between January 2010 and June 2012, 47 patients were enrolled from 12 institutions. Wild-type or mutant KRAS sequences were examined in 32 and 15 patients, respectively. Twenty-one (45 %) patients experienced Grades 3/4 adverse events, and 55 % of all patients responded to therapy. The sizes of tumors of patients in the wild-type KRAS group were significantly reduced compared with those of the mutant KRAS group. The overall rates of liver resection and postoperative morbidity were 83 and 14 %, respectively, and the median PFS was 15.6 months. The median PFS times of the KRAS wild-type and mutant groups were 22.5 months and 10.5 months, respectively. CONCLUSIONS: Neoadjuvant therapy using FOLFOX/XELOX combined with monoclonal antibodies did not improve PFS, although it was administered safely and had less adverse effects after liver resection.

DOI： 10.1245/s10434-016-5557-9

Web of Science

PubMed

Proposal of the Coagulation Score as a Predictor for Short-Term and Long-Term Outcomes of Patients with Resectable Gastric Cancer Reviewed

Mitsuro Kanda, Chie Tanaka, Daisuke Kobayashi, Akira Mizuno, Yuri Tanaka, Hideki Takami, Naoki Iwata, Masamichi Hayashi, Yukiko Niwa, Suguru Yamada, Tsutomu Fujii, Hiroyuki Sugimoto, Kenta Murotani, Michitaka Fujiwara, Yasuhiro Kodera

ANNALS OF SURGICAL ONCOLOGY Vol. 24 ( 2 ) page： 502 - 509 2017.2

Language：Japanese Publishing type：Research paper (scientific journal) Publisher：SPRINGER

Systemic hemostasis and thrombosis activation has been implicated in tumor progression and metastasis. This study aimed to investigate the use of coagulation factors as a novel prediction method for postoperative outcomes after curative gastrectomy in patients with stage II/III gastric cancer (GC).
Overall, 126 patients with stage II/III GC who underwent gastrectomy between May 2003 and February 2016 were eligible for inclusion in the study. We retrospectively evaluated the predictive value of preoperative platelet count and plasma fibrinogen and d-dimer levels, and coagulation score (0: fibrinogen and d-dimer both below upper limits; 1: either fibrinogen or d-dimer over upper limits; 2: both fibrinogen and d-dimer over upper limits) for short- and long-term outcomes.
Postoperative complications were significantly more frequent in patients with elevated preoperative d-dimer levels compared with those with normal d-dimer levels (26 vs. 10 %; p = 0.032). The prevalence of postoperative complications showed a stepwise increase in proportion to the coagulation score. Patients with a coagulation score of 2 had significantly larger tumors (p = 0.013) and significantly greater intraoperative blood loss (p = 0.004) than those who scored 0 or 1. Coagulation score showed the highest values distinguished high-risk patients in overall and disease-free survival, and a coagulation score of 2 was an independent prognostic factor for recurrence. Patients with a coagulation score of 2 experienced a significantly higher prevalence of liver metastasis as an initial recurrence than those who scored 0 or 1 (p = 0.019).
The coagulation score is a simple and promising predictor for postoperative complications and recurrence after gastrectomy in stage II/III GC patients.

DOI： 10.1245/s10434-016-5544-1

Web of Science

PubMed

The protein arginine methyltransferase 5 promotes malignant phenotype of hepatocellular carcinoma cells and is associated with adverse patient outcomes after curative hepatectomy Reviewed

Dai Shimizu, Mitsuro Kanda, Hiroyuki Sugimoto, Masahiro Shibata, Haruyoshi Tanaka, Hideki Takami, Naoki Iwata, Masamichi Hayashi, Chie Tanaka, Daisuke Kobayashi, Suguru Yamada, Goro Nakayama, Masahiko Koike, Michitaka Fujiwara, Tsutomu Fujii, Yasuhiro Kodera

INTERNATIONAL JOURNAL OF ONCOLOGY Vol. 50 ( 2 ) page： 381 - 386 2017.2

Language：Japanese Publishing type：Research paper (scientific journal) Publisher：SPANDIDOS PUBL LTD

The prognosis of advanced hepatocellular carcinoma (HCC) is dismal. Novel molecular targets for diagnosis and therapy is urgently required. This study evaluated expression and functions of the protein arginine methyltransferase 5 (PRMT5) in HCC. Using HCC cell lines, the expression levels of PRMT5 mRNA were determined using the quantitative real-time reverse-transcription polymerase chain reaction, and the effect of a small interfering PRMT5-siRNA on cell phenotype was evaluated. Further, PRMT5 expression was determined in 144 pairs of resected liver tissues to evaluate its clinical significance. Regardless of their differentiated phenotypes, nine HCC cell lines expressed different levels of PRMT5 mRNA. Inhibition of PRMT5 expression significantly decreased the proliferation, invasion, and migration of HCC cell lines. Although the level of PRMT5 mRNA was not influenced by patient's background liver status, it was significantly higher in HCC tissues than in the corresponding noncancerous tissues. High levels of PRMT5 mRNA in HCC tissues were significantly associated with advanced disease stage and adverse prognosis. In conclusion, our results indicate that PRMT5 may act as a putative oncogene in HCC and that the levels of PRMT5 mRNA represent a promising prognostic marker and a potential target of molecular therapy for HCC.

DOI： 10.3892/ijo.2017.3833

Web of Science

PubMed

Association of Inflammasome Components in Background Liver with Poor Prognosis After Curatively-resected Hepatocellular Carcinoma Reviewed

Fuminori Sonohara, Yoshikuni Inokawa, Mitsuro Kanda, Yoko Nishikawa, Suguru Yamada, Tsutomu Fujii, Hiroyuki Sugimoto, Yasuhiro Kodera, Shuji Nomoto

ANTICANCER RESEARCH Vol. 37 ( 1 ) page： 293 - 300 2017.1

Language：Japanese Publishing type：Research paper (scientific journal) Publisher：INT INST ANTICANCER RESEARCH

Background/Aim: Inflammasomes are multiprotein complexes that evoke key inflammatory cascades. The present study evaluated the influence of inflammasome component expression in non-tumorous tissue on postsurgical hepatocellular carcinoma (HCC) prognosis. Materials and Methods: The expressions of candidate genes were investigated using real-time quantitative reverse-transcription polymerase chain reaction in resected HCC cases. In order to identify potential prognostic factors, statistical analyses were performed for each gene. Results: The expression of nod-like receptor family, pyrin domain containing 3 (NLRP3), nod-like receptor family, CARD domain containing 4 (NLRC4), and absent in melanoma 2 (AIM2) was significantly higher in corresponding normal tissue (CN) compared to those in HCC. High expression of NLRP3, NLRC4, and caspase 1 (CASP1) in CN was significantly correlated with worse overall survival. Furthermore, multivariate analysis revealed that NLRP3 expression in CN greater than the median was an independent prognostic factor for poorer overall survival. Conclusion: High expression of NLRP3, NLRC4, and CASP1 in background non-tumorous liver is significantly correlated with poor prognosis of patients after resection of HCC.

DOI： 10.21873/anticanres.11320

Web of Science

PubMed

Clinical benefits of neoadjuvant chemoradiotherapy for adenocarcinoma of the pancreatic head: an observational study using inverse probability of treatment weighting Reviewed

Tsutomu Fujii, Sohei Satoi, Suguru Yamada, Kenta Murotani, Hiroaki Yanagimoto, Hideki Takami, Tomohisa Yamamoto, Mitsuro Kanda, So Yamaki, Satoshi Hirooka, Masanori Kon, Yasuhiro Kodera

JOURNAL OF GASTROENTEROLOGY Vol. 52 ( 1 ) page： 81 - 93 2017.1

Language：Japanese Publishing type：Research paper (scientific journal) Publisher：SPRINGER JAPAN KK

The efficacy of neoadjuvant chemoradiotherapy (NACRT) and subset of pancreatic ductal adenocarcinoma (PDAC) patients who are most likely to benefit from this strategy remain elusive. The aim of this study was to investigate the effects of NACRT in patients with resectable (R) or borderline resectable (BR) adenocarcinoma of the pancreatic head. BR diseases were classified into two groups: lesions involving exclusively the portal vein system (BR-PV) and those abutting the major artery (BR-A).
A total of 504 patients treated with curative intent for PDAC were analyzed (R, n = 273; BR-PV, n = 129; BR-A, n = 102). Patients who underwent upfront surgery and those who underwent NACRT followed by surgery were compared using propensity score-matched and inverse probability of treatment-weighted analyses (UMIN000019719).
No significant differences were noted in the incidences of curative resection among the three categories (R, BR-PV and BR-A). Propensity score-weighted logistic regression analysis revealed that the incidence of pathologically positive resection margins was reduced by NACRT only for BR patients. Among the propensity score-matched patients, NACRT rather than upfront surgery significantly prolonged the median survival time of BR-PV patients (28.4 vs. 20.1 months; P = 0.044) but not that of R-PDAC patients (28.6 vs. 33.7 months; P = 0.960). NACRT prolonged the median survival time of BR-A patients (18.1 vs. 10.0 months; P = 0.046), but the results remained unsatisfactory.
These findings suggest that NACRT improves R0 rates and increases the survival of patients with BR-PV adenocarcinoma of the pancreatic head but not that of patients with R-PDAC.

DOI： 10.1007/s00535-016-1217-x

Web of Science

PubMed

PAX5 gene as a novel methylation marker that predicts both clinical outcome and cisplatin sensitivity in esophageal squamous cell carcinoma Reviewed

Keisuke Kurimoto, Masamichi Hayashi, Rafael Guerrero-Preston, Masahiko Koike, Mitsuro Kanda, Sho Hirabayashi, Hiroshi Tanabe, Nao Takano, Naoki Iwata, Yukiko Niwa, Hideki Takami, Daisuke Kobayashi, Chie Tanaka, Suguru Yamada, Goro Nakayama, Hiroyuki Sugimoto, Tsutomu Fujii, Michitaka Fujiwara, Yasuhiro Kodera

EPIGENETICS Vol. 12 ( 10 ) page： 865 - 874 2017

Language：Japanese Publishing type：Research paper (scientific journal) Publisher：TAYLOR & FRANCIS INC

Therapeutic strategies for esophageal cancer largely depend on histopathological assessment. To select appropriate treatments of individual patients, we examined the background molecular characteristics of tumor malignancy and sensitivity to multidisciplinary therapy. Seventy-eight surgically-resected esophageal squamous cell carcinoma (ESCC) cases during 2001-2013 were examined. PAX5, a novel gene methylation marker in ESCC, was evaluated in the specimens, as methylation of this gene was identified as an extremely tumor-specific event in squamous cell carcinogenesis of head and neck. PAX5 methylation status was evaluated by quantitative MSP (QMSP) assays. Mean QMSP value was 15.7 (0-136.3) in ESCCs and 0.3 (0-8.6) in adjacent normal tissues (P < 0.001). The 78 cases were divided into high QMSP value (high QMSP, n D 26) and low QMSP value (low QMSP, n D 52). High QMSP cases were significantly associated with downregulated PAX5 expression (P D 0.040), and showed significantly poor recurrencefree survival [Hazard Ratio (HR) D 2.84; P D 0.005; 95% Confidence Interval (CI): 1.39-5.81] and overall survival (HR D 3.23; P D 0.002; 95% CI: 1.52-7.01) in multivariable analyses with histopathological factors. PAX5-knockdown cells exhibited significantly increased cell proliferation and cisplatin resistance. PAX5 gene methylation can predict poor survival outcomes and cisplatin sensitivity in ESCCs and could be a useful diagnostic tool for cancer therapy selection.

DOI： 10.1080/15592294.2017.1365207

Web of Science

PubMed

Hazard rate of tumor recurrence over time in patients with colon cancer: implications for postoperative surveillance from three Japanese Foundation for Multidisciplinary Treatment of Cancer (JFMC) clinical trials. Reviewed International journal

Hiromichi Maeda, Kosuke Kashiwabara, Toru Aoyama, Koji Oba, Michitaka Honda, Shuhei Mayanagi, Mitsuro Kanda, Chikuma Hamada, Sotaro Sadahiro, Junichi Sakamoto, Shigetoyo Saji, Takaki Yoshikawa

Journal of Cancer Vol. 8 ( 19 ) page： 4057 - 4064 2017

Language：Japanese Publishing type：Research paper (scientific journal)

Purpose: Reliable risk estimates of recurrence are necessary to establish optimal postoperative surveillance strategies. The purpose of the present study was to clarify changes in the hazard rate (HR) for tumor recurrence over time in Japanese patients with colon cancer. Methods: Data for 3984 patients from three clinical trials evaluating the benefit of adjuvant chemotherapy for colon cancer were analyzed. Estimated HRs were plotted over time for the entire cohort, as well as for node-positive and node-negative patients separately. The changes in risk were further analyzed according to eight clinical variables, and factors predictive of early (<3 years) and late (>3 years) recurrence were explored using Cox's regression analysis. Results: In node-positive patients, there was a prominent HR peak 0.6 years after surgery, whereas HR remained at consistently low levels in node-negative patients. In node-positive patients, HR decreased steadily until 3 years, after which the decline in HR plateaued. Those with T4 tumors had a prominent HR peak around 1 year, including node-negative patients. The HR for T1/T2 Stage III colon cancers showed a similar pattern as that for T1-T3 node-negative colon cancers. Cox regression analysis revealed that a lack of adjuvant chemotherapy, positive node status, T3/T4 factors, and male gender predict early recurrence, whereas patients with lymph node metastasis, T4 tumors, and a lesser extent of lymph node removal have a higher risk of recurrence 3-4 years after surgery (P<0.05). Conclusion: The present study supports the concept of intensive surveillance during the first 3 years after curative resection. However, a reduction in surveillance intensity may be acceptable for patients with T3 Stage II and T1/T2 Stage III colon cancer.

DOI： 10.7150/jca.21365

Web of Science

PubMed

Pharmacokinetic dose adjustment of 5-FU in modified FOLFOX7 plus bevacizumab for metastatic colorectal cancer in Japanese patients: a-JUST phase II clinical trial. Reviewed

Denda T, Kanda M, Morita Y, Kim HM, Kashiwada T, Matsuda C, Fujieda S, Nakata K, Murotani K, Oba K, Sakamoto J, Mishima H

Cancer chemotherapy and pharmacology Vol. 78 ( 6 ) page： 1253-1261 2016.12

Prognostic significance of AKR1B10 gene expression in hepatocellular carcinoma and surrounding non-tumorous liver tissue.

Sonohara F, Inokawa Y, Hishida M, Kanda M, Nishikawa Y, Yamada S, Fujii T, Sugimoto H, Kodera Y, Nomoto S

Oncology letters Vol. 12 ( 6 ) page： 4821-4828 2016.12

Prognostic relevance of <i>SAMSN1</i> expression in gastric cancer.

Kanda M, Shimizu D, Sueoka S, Nomoto S, Oya H, Takami H, Ezaka K, Hashimoto R, Tanaka Y, Kobayashi D, Tanaka C, Yamada S, Fujii T, Nakayama G, Sugimoto H, Koike M, Fujiwara M, Kodera Y

Oncology letters Vol. 12 ( 6 ) page： 4708-4716 2016.12

A resected case of symptomatic acinar cell cystadenoma of the pancreas displacing the main pancreatic duct.

Tanaka H, Hatsuno T, Kinoshita M, Hasegawa K, Ishihara H, Takano N, Shimoyama S, Nakayama H, Kataoka M, Ichihara S, Kanda M, Kodera Y, Kondo K

Surgical case reports Vol. 2 ( 1 ) page： 39 2016.12

Lymph node ratio as parameter of regional lymph node involvement in pancreatic cancer.

Yamada S, Fujii T, Hirakawa A, Kanda M, Sugimoto H, Kodera Y

Langenbeck's archives of surgery Vol. 401 ( 8 ) page： 1143-1152 2016.12

Erratum to: The COMET Open-label Phase II Study of Neoadjuvant FOLFOX or XELOX Treatment Combined with Molecular Targeting Monoclonal Antibodies in Patients with Resectable Liver Metastasis of Colorectal Cancer. Reviewed

Kataoka M, Kanda M, Ishigure K, Matsuoka H, Sato Y, Takahashi T, Tanaka C, Deguchi T, Shibata Y, Sato M, Inagaki H, Matsui T, Kondo A, Takano N, Tanaka H, Sakamoto J, Oba K, Kondo K

Annals of surgical oncology Vol. 23 ( Suppl 5 ) page： 1064 2016.12

Epigenetic suppression of the immunoregulator MZB1 is associated with the malignant phenotype of gastric cancer. Reviewed

Kanda M, Tanaka C, Kobayashi D, Tanaka H, Shimizu D, Shibata M, Takami H, Hayashi M, Iwata N, Niwa Y, Yamada S, Fujii T, Nakayama G, Fujiwara M, Kodera Y

International journal of cancer Vol. 139 ( 10 ) page： 2290-8 2016.11

Molecular alterations in the carcinogenesis and progression of hepatocellular carcinoma: Tumor factors and background liver factors.

Inokawa Y, Inaoka K, Sonohara F, Hayashi M, Kanda M, Nomoto S

Oncology letters Vol. 12 ( 5 ) page： 3662-3668 2016.11

Predictive value of drain amylase content for peripancreatic inflammatory fluid collections after laparoscopic (assisted) distal gastrectomy. Reviewed

Kanda M, Fujiwara M, Tanaka C, Kobayashi D, Iwata N, Mizuno A, Yamada S, Fujii T, Nakayama G, Sugimoto H, Koike M, Kodera Y

Surgical endoscopy Vol. 30 ( 10 ) page： 4353-62 2016.10

Modified two-dimensional response as surrogate marker of overall survival in patients with metastatic colorectal cancer.

Nakayama G, Fujii T, Murotani K, Uehara K, Hattori N, Hayashi M, Tanaka C, Kobayashi D, Kanda M, Yamada S, Sugimoto H, Koike M, Fujiwara M, Ando Y, Kodera Y

Cancer science Vol. 107 ( 10 ) page： 1492-1498 2016.10

Protein arginine methyltransferase 5 is associated with malignant phenotype and peritoneal metastasis in gastric cancer. Reviewed

Kanda M, Shimizu D, Fujii T, Tanaka H, Shibata M, Iwata N, Hayashi M, Kobayashi D, Tanaka C, Yamada S, Nakayama G, Sugimoto H, Koike M, Fujiwara M, Kodera Y

International journal of oncology Vol. 49 ( 3 ) page： 1195-202 2016.9

Correlation Between Poor Prognosis and Lower TPPP Gene Expression in Hepatocellular Carcinoma.

Inokawa Y, Sonohara F, Kanda M, Hayashi M, Nishikawa Y, Sugimoto H, Kodera Y, Nomoto S

Anticancer research Vol. 36 ( 9 ) page： 4639-45 2016.9

　 PREV - NEXT 　

<KANDA Mitsuro>

Papers - KANDA Mitsuro